key: cord-0989613-hw8eyhr4
authors: Farsalinos, Konstantinos; Barbouni, Anastasia; Niaura, Raymond
title: Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Reply
date: 2020-09-21
journal: Intern Emerg Med
DOI: 10.1007/s11739-020-02457-2
sha: 0032255a09676f995df8bfad6be8de89bbbc2453
doc_id: 989613
cord_uid: hw8eyhr4

nan

COVID-19 that requires hospitalization. Additionally, the lower than expected prevalence of smoking among hospitalized COVID-19 patients is not contradictory to the reported higher odds for adverse outcome in hospitalized smokers compared to non-smokers. In our most recent systematic review and meta-analysis of 30 studies, we reported both an unexpectedly low prevalence of smoking among hospitalized COVID-19 patients and higher odds for adverse outcome in hospitalized smokers [5] . In reality, the evidence suggests that any association between smoking and disease outcome cannot not be generalized to the whole population of smokers but should refer specifically to the seemingly low proportion of smokers who develop severe COVID-19 necessitating hospitalization. One potential explanation for the adverse outcome among hospitalized smokers is that they experience abrupt nicotine cessation from the moment they are admitted to the hospital (unless they are given nicotine replacement therapies). As a result, these patients will be deprived of any potentially beneficial effects of nicotine, which may be related to the activation of the cholinergic anti-inflammatory pathway and/or the prevention of a direct interaction between SARS-CoV-2 and nicotinic acetylcholine receptors, as we have presented in our hypothesis [2, 5] . Concerning the effects of smoking on ACE2 expression, there is highly conflicting and contradictory evidence [2, 5] . Even if smoking was found to up-regulate ACE2, this does not necessarily imply adverse prognosis. In fact, ACE2 has strong anti-inflammatory, anti-oxidant and antifibrotic properties, and it is possible that ACE2 upregulation is protective against severe COVID-19 despite being used by SARS-CoV-2 as a receptor for cell entry [5] . Finally, we take this opportunity to emphasize once again that smoking cannot be considered a protective factor for COVID-19, and smokers should still be encouraged to quit. However, the potential therapeutic effects of nicotine or other nicotinic cholinergic agonists should be further explored in in vitro studies and clinical trials. Ethical approval Not applicable.

Informed consent Not applicable.

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Comment

Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?

Smoking and the risk of COVID-19 in a large observational population study

National smoking rates correlate inversely with COVID-19 mortality

Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis